Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

House dust mite allergy immunotherapy - DMS Imaging

Next Previous
Search
Drug Profile

House dust mite allergy immunotherapy - DMS Imaging

Alternative Names: hdm-ASIT+

Latest Information Update: 18 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ASIT biotech
  • Developer DMS Imaging
  • Class Allergens; Allergy immunotherapies; Antiallergics; Peptides
  • Mechanism of Action Immunomodulators; T lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Rhinoconjunctivitis

Highest Development Phases

  • No development reported Rhinoconjunctivitis

Most Recent Events

  • 18 Feb 2022 No development reported - Phase-II for Rhinoconjunctivitis in Germany (SC)
  • 05 Nov 2018 House dust mite allergy immunotherapy is available for licensing as of 05 Nov 2018. www.asitbiotech.com 809253616
  • 17 Oct 2017 ASIT biotech has patent protection for House dust mite allergy immunotherapy in Europe, China, Japan and India

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top